|
Video: What is a Stock Split?
|
|
Exact Sciences is a cancer screening and diagnostics company. Co.'s primary screening product, the Cologuard® test, is a non-invasive stool-based DNA screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Co.'s portfolio of Oncotype tests include: Oncotype DX gene expression tests for breast, prostate and colon cancers; Oncotype DX AR-V7 Nucleus Detect® test, a liquid-based test for advanced stage prostate cancer; and Oncotype MAP Pan-Cancer Tissue test (oncomap test), a test delivering tumor profiling to aid therapy selection for patients with metastatic, refractory or recurrent cancer. According to our EXACT Sciences stock split history records, EXACT Sciences has had 0 splits. | |
|
EXACT Sciences (EXAS) has 0 splits in our EXACT Sciences stock split history database.
Looking at the EXACT Sciences stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into EXACT Sciences shares, starting with a $10,000 purchase of EXAS, presented on a split-history-adjusted basis factoring in the complete EXACT Sciences stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/01/2014 |
|
End date: |
03/28/2024 |
|
Start price/share: |
$14.16 |
|
End price/share: |
$69.06 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
387.71% |
|
Average Annual Total Return: |
17.18% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$48,791.74 |
|
Years: |
10.00 |
|
|
|
|
|